---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-001665"
form_type: "8-K"
ticker: "AEON"
cik: "0001837607"
company_name: "AEON Biopharma, Inc."
filed_at: "2025-01-07T23:59:59+00:00"
generated_at: "2026-05-28T09:05:03.716733+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# AEON Biopharma closes $20M public offering; net proceeds ~$18.3M

## Summary
- Gross proceeds ~$20M from 40M common units at $0.50/unit (1 share + 1 Series A + 1 Series B warrant).
- Net proceeds after underwriting fees ~$18.3M; over-allotment added 6M Series A and 6M Series B warrants.
- Funds expected to support operations through 2025 and advance ABP-450 biosimilar development.
- After offering, shares outstanding ~79.97M; warrants exercisable at $0.625/share post-stockholder approval.
- CEO Marc Forth highlighted sufficient capital for 351(k) regulatory pathway and planned BPD Type 2 meeting.

## SEC filing metadata
- accession: 0001104659-25-001665
- form_type: 8-K
- ticker: AEON
- cik: 0001837607
- company_name: AEON Biopharma, Inc.
- filed_at: 2025-01-07T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1837607/000110465925001665/0001104659-25-001665-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1837607/000110465925001665/tm2432042d4_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-001665
- JSON: https://secwatch.observer/filing/0001104659-25-001665.json
- Plain text: https://secwatch.observer/filing/0001104659-25-001665.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.